Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials
| Autor: | Lawren C. Wu, Jackson G. Egen, Wenjun Ouyang |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Cell type T-Lymphocytes medicine.medical_treatment Programmed Cell Death 1 Receptor Immunology Lymphocyte Activation B7-H1 Antigen 03 medical and health sciences 0302 clinical medicine Immunity Neoplasms Tumor Microenvironment medicine Humans Immunology and Allergy CTLA-4 Antigen Tumor microenvironment biology Antitumor immunity Antibodies Monoclonal Cancer Immunotherapy medicine.disease Clinical trial 030104 developmental biology Infectious Diseases 030220 oncology & carcinogenesis Cancer research biology.protein Antibody |
| Zdroj: | Immunity. 52:36-54 |
| ISSN: | 1074-7613 |
| Popis: | Therapeutics that target the T cell inhibitory checkpoint proteins CTLA-4 and PD(L)1 are efficacious across a broad range of cancers, resulting in reductions in tumor burden and increased long-term survival in subsets of patients. The significant and wide-ranging effects of these immunotherapies have prompted the clinical investigation of additional therapies that modulate anti-tumor immunity through effects on T cells, myeloid cells, and other cell types within the tumor microenvironment. The clinical activity of these newer investigational therapies has been mixed, with some therapeutics showing promise but others not exhibiting appreciable efficacy. In this review, we summarize the results of select recent clinical studies of cancer immunotherapies beyond anti-CTLA-4 and anti-PD(L)1 and discuss how these results are providing new insights into the regulation of human anti-tumor immunity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|